A new guideline from the US has neatly summarized the evidence regarding the use of 5α-reductase inhibitors for prostate disease, but falls short of providing definitive management recommendations. It will, however, be a valuable aid to both patients and physicians in the clinical decision-making process.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prediction of small-for-gestational-age neonates at 33–39 weeks’ gestation in China: logistic regression modeling of the contributions of second- and third-trimester ultrasound data and maternal factors
BMC Pregnancy and Childbirth Open Access 25 August 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
AUA Guidelines 2009 American Urological Association [online] (2009).
EAU Guidelines 2009 European Association of Urology [online] (2009).
McConnell, J. D. et al. The long-term effect of doxazocin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 349, 2387–2398 (2003).
Klotz, L. & Clarke, N. W. Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5α-reductase inhibitor to prevent prostate cancer. Eur. Urol. 53, 1079–1083 (2008).
Kramer, B. S. et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Urol. 181, 1642–1647 (2009).
Kramer, B. S. et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J. Clin. Oncol. 27, 1502–1516 (2009).
Thompson, I. M. et al. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 349, 215–224 (2003).
Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).
Andriole G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Clarke, N. Should 5α-reductase inhibitors be used for prostate disease?. Nat Rev Urol 6, 358–359 (2009). https://doi.org/10.1038/nrurol.2009.105
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2009.105
